Results of VHIO-led pharmacokinetic analysis of Omomyc, a therapeutic mini-protein that targets the MYC oncogene which is found deregulated in…
Laura Soucek
Preliminary results from a phase I clinical trial show that the first in class MYC inhibitor Omomyc (OMO-103) has few…
VHIO-led research published in Cancer Research Communications shows that the first-in-class MYC inhibitor Omomyc effectively halts disease progression in metastatic…
Barcelona, August 25, 2021. Multiple myeloma (MM), although relatively rare, is a highly heterogeneous cancer accounting for around 10% of…
Barcelona, June 23, 2021. Published today in the Journal of Cell Biology, a Perspective article* co-authored by VHIO’s Laura Soucek and Jonathan R. Whitfield revisit…
Barcelona, June 18, 2021. VHIO’s MYC ‘Masters’, Laura Soucek and Jonathan Whitfield, have shared their expertise alongside other leading figures in…
Laura Soucek, Principal Investigator of VHIO’s Mouse Models of Cancer Therapies Group, an ICREA Research Professor, and co-Founder and Executive…
Mariano F. Zacarías Fluck, Research Associate of VHIO’s Mouse Models of Cancer Therapies, and co-First Author of this present study….
